PNQ-849

PNQ-849 is an orally bioavailable, reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed by Impetis Biosciences. BTK is a critical mediator in the B-cell receptor (BCR) and Fc receptor signaling pathways, making it a key target for autoimmune and inflammatory disorders. Unlike first-generation covalent BTK inhibitors that bind to the Cys481 residue, PNQ-849's non-covalent binding mechanism may provide advantages in terms of selectivity and the potential to overcome resistance mutations (such as C481S) that render covalent inhibitors ineffective. The program has achieved an IND-ready profile, targeting chronic inflammation and various autoimmune indications.